2.1
Enfortumab vedotin (Padcev, Astellas) with pembrolizumab (Keytruda, MSD) is indicated for 'the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy'.
2 Information about enfortumab vedotin with pembrolizumab
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedules are available in the summary of product characteristics for enfortumab vedotin and summary of product characteristics for pembrolizumab.
Price
2.3
The price of enfortumab vedotin is £578 per 20‑mg vial or £867 per 30‑mg vial (excluding VAT; BNF online accessed August 2025). The price of pembrolizumab is £2,630 per 100 mg in a 4‑ml vial (excluding VAT; BNF online accessed August 2025).
2.4
Astellas has a commercial arrangement for enfortumab vedotin. This makes enfortumab vedotin available to the NHS with a discount. The size of the discount is commercial in confidence.
2.5
MSD has a commercial arrangement for pembrolizumab. This makes pembrolizumab available to the NHS with a discount. The size of the discount is commercial in confidence.
Carbon Reduction Plan
2.6
For information, Astellas' Carbon Reduction Plan for UK carbon emissions is published on Astellas' webpage on sustainability.
2.7
For information, MSD's Carbon Reduction Plan for UK carbon emissions is published on MSD's webpage on responsibility.